1. Impact of Early Treatment with High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children
- Author
-
Shahnaz Alamdari, Alireza Karimi Yazdi, Khadije Toomaj, Yahya Aghighi, Leyla Sahebi, Parvin Akbariasbagh, Seyyed Reza Raeeskarami, and Sahar Heidari
- Subjects
medicine.medical_specialty ,High dose intravenous immunoglobulin ,Immunoglobulins ,Coronary Artery Disease ,Mucocutaneous Lymph Node Syndrome ,Gastroenterology ,Coronary artery disease ,Internal medicine ,medicine ,Aspirin ,biology ,business.industry ,Incidence (epidemiology) ,Obstetrics and Gynecology ,Gynecology and obstetrics ,medicine.disease ,Hearing disorders ,Reproductive Medicine ,biology.protein ,RG1-991 ,Kawasaki disease ,Antibody ,Family Practice ,business ,medicine.drug - Abstract
Objective: Kawasaki disease (KD) occurs in five-year-old or younger children. This study aimed to evaluate the impact of high-dose intravenous immunoglobulin plus acetylsalicylic acid therapy on the prevention and treatment of coronary artery lesions and to evaluate the impact of high-dose acetylsalicylic acid (ASA) on the hearing of the patients. Materials and methods: In this retrospective cohort study, 31 patients with KD were followed from January 2012 to December 2015. The clinical, para-clinical, color Doppler echocardiogram and audiometry results were evaluated. Results: Overall, seven cases (22.6%) developed coronary artery aneurysm (CAA) in the acute phase of the disease, of whom only two still had CAA at the end of the treatment (6%). One of the five children with CAA recovery had a delay in the onset of treatment and one of two patients with persistent CAA at the end of treatment was admitted within the first 10 days. There was no evidence-based abnormal liver biochemical test. None of the patients developed sensorineural hearing loss (SNHL) on audiometry tests conducted before and after treatment. Conclusion: Recovery of coronary artery lesions was 71.43% after 28 days of the onset of treatment. The distribution of coronary artery aneurysm was not different in terms of the time of the treatment initiation (P-Value = 0.371). None of the children had a sensorineural hearing loss (SNHL) 48 hours and 4 weeks after treatment.
- Published
- 2021